

Digirad's New OptiCount™ Product Delivers Higher Sensitivity

San Diego, CA - February 9, 2004 Digirad Corporation, the leader in solid-state imaging, announced today the release of its new OptiCount collimator that increases the organ sensitivity of Digirad's nuclear cardiology imaging systems by an average of 15% per detector head, while maintaining the same level of reconstructed image spatial resolution.

Additionally, when used in conjunction with Digirad's new third generation Solidium™ detectors, OptiCount collimation improves organ sensitivity by at least 30% over specifications listed for some conventional competitive Anger cameras. Increased organ sensitivity generally correlates to improved image quality.

"OptiCount collimation is an important product line extension that improves organ sensitivity in nuclear cardiology applications," said David Sheehan, President and CEO, Digirad Corporation. "While OptiCount offers increased organ sensitivity, the combination of the OptiCount product with Solidium technology also offers our customers an outstanding combination of enhanced sensitivity and reliability. OptiCount collimation represents an impressive milestone in nuclear cardiology that represents the first of many planned products and upgrades designed to improve performance for Digirad's solid-state cameras."

The OptiCount product is available as an optional accessory on new solid-state gamma cameras or as an upgrade to Digirad's existing installed base of cameras.

About Digirad

Digirad Corporation, a privately held company, develops, manufactures and markets solid-state, digital gamma cameras to hospitals, imaging centers and physician offices. Digirad offers a comprehensive line of solid-state nuclear gamma cameras that can be used for the detection of many medical conditions including cardiovascular disease. These high performance cameras produce outstanding image quality, and due to their lightweight and compact design, fit easily into small office spaces.

Digirad Imaging Solutions, a wholly owned subsidiary of Digirad Corporation, provides mobile turnkey, in-office leasing services for physicians who want to perform nuclear cardiology procedures, but do not have the capital, personnel or patient volume to justify purchasing a system. Both Digirad Corporation and Digirad Imaging Solutions are headquartered in San Diego. For more information, please visit www.digirad.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of Digirad Corporation. This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether current trends in sales, growth, revenue, customer satisfaction, technology development, sensitivity, reliance and performance improvements and product development will continue in the future.